Table 5 Mucosal melanoma of the head and neck: a review of the recent literature series (with ≥50 patients & utilizing radiotherapy)
From: Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013
Author | Setting, country | Period of diagnosis | No. of patients | Age | Primary tumor site (%) | TNM stage (%) | Treatment modality (%) | OS (at 5 years, %) | DSS, (at 5 years, %) |
|---|---|---|---|---|---|---|---|---|---|
Median/Mean* (range) | |||||||||
Gal et al., 2011 [29] | Population-based (26 %), USA | 2000–2007 | 304 | 71.2* | SN, all | III, 32.2 | S, 43.1 | 24.2 | NR |
IVA, 25.3 | SRT, 38.5 | ||||||||
IVB, 11.2 | RT, 7.6 | ||||||||
IVC, 12.2 | None/Unknown, 10.9 | ||||||||
Jangard et al., 2013 [13] | Population-based (96 %), Sweden | 1960–2000 | 186 | 72 (31–93) | SN, all | I, 83.9 | S, 53.1 | NR | 20.4 |
II, 2.2 | SRT, 32 | ||||||||
III, 4.3, | SRTSTh, 2.7 | ||||||||
Unknown, 9.7 | Palliative, 12.2 | ||||||||
Benlyazid et al., 2010 [30] | Multi-institutional, France | 1980–2008 | 160 | 67.0 (30–93) | SN, 90.6 | I, 96.3 | S, 51.3 | 37.5 | NR |
OC, 7.5 | II, 3.8 | SRT, 48.8 | |||||||
Other, 1.9 | |||||||||
Lund et al., 2012 [27] | Single institution, UK | 1963–2010 | 115 | 65.9* (15–91) | SN, all | I, 87.8 | S, 55.7 | 28 | NR |
II, 8.7 Unknown, 3.5 | SRT, 44.3 | ||||||||
Shiga et al., 2012 [31] | Multi-institutional, Japan | 1998–2007 | 94 | 68.4* (37–96) | SN, 78.7 | I, 16.0 | S, 9.6 | S + STh/RT, 38.6 | NR |
OC-OP, 15.6 | II, 28.7 | RT, 9.6 | RT+/−STh, 29.9 | ||||||
Unknown primary, 3.2 External ear, 2.1 | III, 9.6 | STh, 7.4 | |||||||
IVA, 31.9 | S + STh/RT, 52.1 | ||||||||
IVB, 3.2 | RT+/−STh, 19.1 | ||||||||
IVC, 10.6 | None, 2.1 | ||||||||
Meng et al., 2014 [32] | Single institution, China | 2000–2010 | 69 | 65.9* (28–89) | SN, all | III, 53.6 | S, 39.1 | S, 31.6 | NR |
IVA, 39.1 | SRT, 34.8 | SRT, 55 | |||||||
IVB, 7.2 | SRTSTh, 26.1 | SRTSTh, 32.1 | |||||||
Sun et al., 2014 [33] | Single institution, China | 1976–2005 | 68 | 55 (2–79) | SN, all | III, 52.9 | S, 27.7 | 29.7 | NR |
IVA, 35.3 | RT, 6.2 | ||||||||
IVB, 5.9 | STh, 12.3 | ||||||||
IVC, 5.9 | SRT, 20.0 | ||||||||
S + STh, 29.2 | |||||||||
RT + STh, 3.1 | |||||||||
SRTSTh, 1.5 | |||||||||
Douglas et al., 2010 [34] | Single institution, UK | 1965–2001 | 68 | 63 (29–86) | SN, 65 | I, 80 | S, 27 | 22 | 32 |
OC, 19 | II, 19 | RT, 46 | |||||||
Other, 16 | III, 1 | SRT, 7 | |||||||
Palliative, 20 | |||||||||
Demizu et al., 2014 [35] | Single institution, Japan | 2003–2011 | 62 | 70.5 (33–89) | SN, 90.3 | T1, 27 | RT, all | At 1 year, 93 | NR |
OC, 9.7 | T2, 31 | - protons, 53.2 | At 2 years, 61 | ||||||
T3, 31 | - carbon ion, 46.8 | ||||||||
T4, 11 | Prior treatment: | ||||||||
S, 11.3 | |||||||||
STh, 8.1 | |||||||||
S + STh, 3.2 | |||||||||
Moreno et al., 2010 [19] | Single institution, USA | 1993–2004 | 58 | 63.4 (38–93) | SN, all | I, 87.9 | S, 43.1 | 38.7 | 18.4 |
II, 6.9 | SRT, 53.4 | ||||||||
III, 5.2 | RT, 3.4 | ||||||||
Shuman et al., 2011 [28] | Single institution, USA | 1992–2009 | 52 | 66* | OC, 31 | I, 25.0 | S, 69.2 | 38 | 22 |
SN, 69 | II, 34.6 | SRT, 19.2 | |||||||
III, 11.5 | Palliative RT, 9.6 | ||||||||
IV, 28.8 | |||||||||
Sun et al., 2012 [36] | Single institution, China | 1976–2005 | 51 | 55 (31–75) | OC, all | III, 23.5 | S, 76.5 | 20.7 | NR |
IVA, 34 | SRT, 3.9 | ||||||||
IVB, 4 | STh, 11.8 | ||||||||
IVC, 1 | None, 7.8 | ||||||||
Koivunen et al., 2012 [37] | Multi-institutional, Finland | 1990–2004 | 50 | 70* (46–93) | SN, all | III, 36 | S, 66.0 | 27 | 48 |
IVA, 42 | SRT, 14.0 | ||||||||
IVB, 20 | RT, 14.0 | ||||||||
IVC, 2 | |||||||||
Current series, 2016 | Population-based, Slovenia | 1986–2013 | 61 | 75.5 (25–91) | SN, 72 | III, 34 | Curative intent | Whole cohort, 18 Curative intent, 24 | Curative intent, 25 |
OC-OP, 26 | IVA, 49 | (N = 48): | |||||||
Middle ear, 1.6 | IVB, 12 | S, 44 | |||||||
IVC, 4.9 | SRT, 33 | ||||||||
RT, 23 |